<DOC>
	<DOCNO>NCT00928083</DOCNO>
	<brief_summary>OZ439 synthetic trioxolane potential value peroxide antimalarial agent . This Phase I , single-centre , multi-component , double-blind , randomised , placebo-controlled study healthy male female subject . The study conduct 3 part : - Part A investigated safety , tolerability pharmacokinetics ( PK ) single oral escalating dos OZ439 . Up 6 dose level investigate estimate dose proportionality . - Part B , effect food single oral dose OZ439 investigate 2-way crossover design . - Part C investigate safety , tolerability PK profile multiple oral dos OZ439 . The start oral dose 50 mg maximum single dose administer exceed 1600 mg per subject . The maximum duration dose propose 3 day .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability Pharmacokinetics OZ439 Healthy Male Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<criteria>1 . Healthy male//female subject 18 55 year age ( inclusive ) . 2 . Body mass Index ( BMI ) 18 30 kg/m2 , inclusive ; total body weight &gt; 60 kg ( 132 lb ) . 3 . Healthy determine prestudy medical history , PE , 12 Lead ECG . 4 . Females childbearing potential must use 1 birth control method throughout study 30 day last dose study drug : 1 . Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum prior first dose study drug . 2 . Intrauterine device ( IUD ) place least 3 month prior first dose study drug . 3 . Barrier method ( condom diaphragm ) spermicide start least 14 day prior first dose study drug 30 day last dose study drug . 4 . Surgical sterilization partner ( ) ( vasectomy zero sperm count 6 month minimum prior first dose study drug ) . 5 . Hormonal contraceptive start least 3 month prior first dose study drug . In addition , subject must agree use barrier method ( condom diaphragm ) spermicide least 14 day prior first dose study drug 30 day last dose study drug . 5 . Postmenopausal woman amenorrhea least 1 year eligible confirm FSH . 6 . Male subject must agree use double barrier method contraception , time first dose study drug 90 day last dose study drug must also agree donate sperm 90 day last dose study drug . Clinical laboratory test within reference range . 7 . Able/willing give write informed consent . 8 . Willing/to adhere lifestyle guideline restriction outline protocol . 9 . Willing able confined Clinical Research Unit require protocol . 1 . Evidence/history clinically significant oncologic , pulmonary , hepatic , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease , current infection . 2 . Evidence/history clinically significant gastrointestinal ( exclusion exist ) disease , current infection . 3 . Any condition affect drug absorption , e.g. , gastrectomy . 4 . History postantibiotic colitis . 5 . Breast feeding . 6 . QTc great 450 msec male 470 msec female correct Bazett formula . 7 . History drug alcohol abuse within past 2 year prior Screening . 8 . Tobacco user 9 . Received investigational drug/ participate another research study within 30 day first dose study drug part study . 10 . Use prescription drug within 14 day prior first dose study drug Period 1 , need antibiotic study . 11 . Received non prescription med , vitamin , herbal/dietary supplement within 7 day administration first dose study drug Period 1 ( exception exist ) 12 . Consumed alcohol within 72 hour Day 1 part study , positive alcohol screen screen admission Clinical Research Unit ( CRU ) . 13 . Consumed grapefruit juice juice contain grapefruit ate grapefruit within 7 day prior first dose study drug part study . 14 . Positive serum pregnancy test Screening Visit Day 1 prior inclusion part study . 15 . Positive test HIV1 , HBsAg , HCV . 16 . Positive urine drug screen Screening admission CRU . 17 . History intolerance/ hypersensitivity artemisinins . 18 . Likelihood require treatment study period drug permit protocol . 19 . Subjects donate blood experienced significant blood loss within 60 day screen study . 20 . Subjects whose hemoglobin &lt; 12.5 g/dL males/ &lt; 11.5 g/dL female . 21 . Any concern investigator regard safe participation subject study reason investigator considers subject inappropriate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Safety tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>synthetic peroxide</keyword>
	<keyword>trioxolane</keyword>
	<keyword>treatment erythrocytic stage malaria</keyword>
</DOC>